Catalyst Wire Dossier Catalyst Wire Dossier
FDA approval · 2022-01-26

FDA Approved: BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE — Original Application (GLENMARK PHARMACEUTICALS INC., USA)

View source ↗

Summary

FDA approved an original application for a generic fixed-dose combination drug of bisoprolol fumarate and hydrochlorothiazide for hypertension.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

Drugs mentioned

  • Bisoprolol Fumarate and Hydrochlorothiazide (bisoprolol fumarate and hydrochlorothiazide)

Snippet

ORIG AP for BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE (BISOPROLOL FUMARATE AND HYDROCHLOROTHIAZIDE)